

Cendakimab Biosimilar - Research Grade

Product Code: ICH5432

More Information

Species Reactivity: Human

Target: IL13 α 1/2

Concentration: 5mg/ml

Isotype: IgG1 - kappa

Host: CHO Cells

product name H2: Cendakimab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: P35225

Shipping Conditions: Blue ice

background: Interleukin-13 (IL-13) is a type 2 cytokine that drives allergic inflammation, mucus production and fibrosis, a widely studied axis in asthma and atopic-disease research. Provided as an unconjugated, non-therapeutic analog of cendakimab, this human IgG1-kappa recombinant antibody is for research use only (RUO). It is supplied with low endotoxin to in vivo-grade standards and produced in scalable milligram-to-gram quantities for high-throughput laboratories. The antibody supports functional and neutralization assays, cytokine-signaling studies, in vitro screening and preclinical type 2 inflammation models centered on IL-13. Its low-endotoxin, in vivo-grade formulation and scalable milligram-to-gram supply make it dependable for repeat, high-volume experimentation.

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.



Purity: >90% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks